主要文件

查看所有文档

N3538

那格列奈

Name: 那格列奈
Brand: SIGMA

≥98% (HPLC), solid

别名:

Fastic, N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine, Starlix, Starsis

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₉H₂₇NO₃

化学文摘社编号:

105816-04-4

分子量:

317.42

NACRES:

NA.77

PubChem Substance ID:

329818636

UNSPSC Code:

12352200

MDL number:

MFCD00875706

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white to off-white

solubility

DMSO: >5 mg/mL, H₂O: insoluble

originator

Novartis

storage temp.

room temp

SMILES string

CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O

InChI

1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1

InChI key

OELFLUMRDSZNSF-BRWVUGGUSA-N

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

说明

Biochem/physiol Actions

Nateglinide is a K_ir6.2/SUR1 channel inhibitor and antidiabetic.

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.

Nateglinide is a short-acting insulin secretagogue useful in treating type 2 diabetes. It is an insulinotropic agent effective for postprandial hyperglycemia. Nateglinide restores prandial insulin levels in a glucose-dependent manner.

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under 那格列奈

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Potassium Channels

We offer many products related to potassium channels for your research needs.

钾通道

我们可提供多种与钙通道相关的产品以满足您的各类研究需求。

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Julio Rosenstock et al.

Diabetes care, 27(6), 1265-1270 (2004-05-27)

A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. Enrolled patients (n = 150) had received treatment with diet and

From evidence assessments to coverage decisions?: the case example of glinides in Germany.

Julia Kreis et al.

Health policy (Amsterdam, Netherlands), 104(1), 27-31 (2011-12-06)

In Germany, coverage decisions in the statutory health insurance (SHI) system are based on the principles of evidence-based medicine. Recently, an evidence assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) of the oral antidiabetics of the

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

Carola Saloranta et al.

The Journal of clinical endocrinology and metabolism, 87(9), 4171-4176 (2002-09-06)

Nateglinide is a fast-acting insulin secretion agent that specifically targets postprandial hyperglycemia in patients with type 2 diabetes. The recent reduction in the diagnostic criteria for diabetes and improved understanding of the importance of early insulin secretion served as the

查看所有相关文献

全球贸易项目编号

货号	GTIN
N3538-10MG	04061834116189
N3538-50MG	04061832575056